PIK3CA Somatic Mutation Status in Relation to Patient and Tumor Factors in Racial/Ethnic Minorities with Colorectal Cancer
Amanda I Phipps, Dennis J Ahnen, Iona Cheng, Polly A Newcomb, Aung Ko Win, Terrilea Burnett
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION | AMER ASSOC CANCER RESEARCH | Published : 2015
BACKGROUND: Approximately 10% to 20% of colorectal cancers exhibit somatic mutations in the phosphoinositide-3-kinase, catalytic, alpha polypeptide gene (PIK3CA). We evaluated the relationship of PIK3CA mutation status in colorectal cancer with race/ethnicity, colorectal cancer survival, and other patient and tumor factors. METHODS: This study comprised 377 racial/ethnic minorities with incident invasive colorectal cancer, enrolled in the Colon Cancer Family Registry via population-based cancer registries. Tumor specimens were tested for PIK3CA mutations in exon 9 and 20 hotspots, BRAF p.V600E mutations, and DNA mismatch repair (MMR). In logistic regression models, we evaluated the associati..View full abstract
Awarded by National Cancer Institute, National Institutes of Health
Awarded by National Cancer Institute
Awarded by NATIONAL CANCER INSTITUTE
This work was supported by grant UM1 CA167551 (to P.A. Newcomb, A.K. Win, T. Burnett, and D.J. Ahnen) from the National Cancer Institute, National Institutes of Health and through cooperative agreements with members of the C-CFR and Principal Investigators. Collaborating centers include Seattle Colorectal Cancer Family Registry (U01/U24 CA074794, to P.A. Newcomb) and the University of Hawaii Family Registry of Colon Cancer (U01/U24 CA074806, to T. Burnett). This research was also supported by National Cancer Institute grants K07CA172298 (to A.I. Phipps) and K05CA152715 (to P.A. Newcomb).